In­di­ana man­u­fac­tur­er to con­struct fa­cil­i­ty for ra­di­oli­gand pro­duc­tion

As com­pa­nies both large and small are con­tin­u­ing to place bets on ra­di­oli­gand ther­a­pies, the man­u­fac­tur­ing in­dus­try is ex­pand­ing to ac­com­mo­date the ris­ing in­ter­est.

In­di­ana-based Spec­tron­Rx is plan­ning to con­struct a new fa­cil­i­ty for pro­duc­ing ac­tini­um-225, which has yet to win FDA ap­proval. Spec­tron­Rx has se­cured more than 10 acres in Bunker Hill, IN, a town halfway be­tween In­di­anapo­lis and South Bend. The square footage of the fa­cil­i­ty has not been fi­nal­ized, ac­cord­ing to the com­pa­ny, but it will aim to pro­duce Ac-225 for use in clin­i­cal tri­als and com­mer­cial sup­ply of can­cer-fight­ing ther­a­pies.

Ac­cord­ing to Spec­tron­Rx the com­pa­ny is in­vest­ing mil­lions of dol­lars in the project, putting put es­ti­mates north of $20 mil­lion, with plans to hire 25 new em­ploy­ees. The com­pa­ny said it has ap­plied for state eco­nom­ic de­vel­op­ment as­sis­tance to com­plete the project.

John Zehn­er

How­ev­er, while the com­pa­ny is push­ing for­ward with Ac-225 pro­duc­tion, the com­pound isn’t wide­ly used now.

“Al­though there’s cur­rent­ly no (FDA)-ap­proved treat­ment us­ing Ac-225, it’s show­ing great promise when it comes to the treat­ment of cer­tain types of can­cer, in­clud­ing prostate, breast, colon, brain, and neu­roen­docrine,” said John Zehn­er, CEO of Spec­tron­Rx in a state­ment.

In an email to End­points News, Sprec­tron­Rx pres­i­dent An­wer Rizvi said that us­ing Ac-225 is show­ing great promise for treat­ing cer­tain types of can­cer, in­clud­ing prostate, breast, colon, brain and neu­roen­docrine.

“But un­for­tu­nate­ly, there is a lim­it­ed sup­ply of Ac-225, with on­ly small amounts of it be­ing pro­duced by var­i­ous gov­ern­ment en­ti­ties. This lim­its the abil­i­ty of phar­ma com­pa­nies to per­form the R&D need­ed to ad­vance the use of this cru­cial ra­dionu­clide. And once treat­ments are ap­proved, sup­plies will be­come even more lim­it­ed with­out bet­ter pro­duc­tion, that’s why Spec­tron­Rx is build­ing this new fa­cil­i­ty,” he said.

Oth­er com­pa­nies have been bull­ish on man­u­fac­tur­ing the com­pound, es­pe­cial­ly in the Hoosier state.

Ear­li­er this year, bio­man­u­fac­tur­er Point re­ceived ac­tini­um-225 from the DOE’s Iso­tope Pro­gram to sup­port its ear­ly-stage pipeline and in-house man­u­fac­tur­ing of lutetium-177, a ra­dioac­tive med­i­cine that binds it­self to tu­mor cells at its new 80,000-square-foot site in In­di­ana that Point billed as one of the largest ra­di­oli­gand fa­cil­i­ties in the world.

Pi­o­neer­ing Click Chem­istry in Hu­mans

Reimagining cancer treatments

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, which is nearly one in six deaths. Recently, we have seen incredible advances in novel cancer therapies such as immune checkpoint inhibitors, cell therapies, and antibody-drug conjugates that have revamped cancer care and improved survival rates for patients.

Despite this significant progress in therapeutic targeting, why are we still seeing such a high mortality rate? The reason is that promising therapies are often limited by their therapeutic index, which is a measure of the effective dose of a drug, relative to its safety. If we could broaden the therapeutic indices of currently available medicines, it would revolutionize cancer treatments. We are still on the quest to find the ultimate cancer medicine – highly effective in several cancer types, safe, and precisely targeted to the tumor site.

Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)

Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Not 24 hours after earning the first ALS drug approval in five years, Amylyx Pharmaceuticals’ Relyvrio is already drawing scrutiny. And it’s coming from multiple fronts.

In an investor call Friday morning, Amylyx revealed that it would charge about $158,000 per year, a price point that immediately drew backlash from ALS advocates and some outside observers. The cost reveal had been highly anticipated in the immediate hours after Thursday evening’s approval, though Amylyx only teased Relyvrio would cost less than previously approved drugs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

After brief stops in Paris and Boston, John Carroll and the Endpoints crew are staying on the road in October with their return for a live/streaming EUBIO22 in London. The hybrid event fireside chats and panels on mRNA, oncology and the crazy public market. We hope you can join him there.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Joshua Cohen (L) and Justin Klee, Amylyx co-CEOs

Up­dat­ed: Af­ter long and wind­ing road, FDA ap­proves Amy­lyx's ALS drug in vic­to­ry for pa­tients and ad­vo­ca­cy groups

For just the third time in its 116-year history, the FDA has approved a new treatment for Lou Gehrig’s disease, or ALS.

US regulators gave the thumbs-up to the drug, known as Relyvrio, in a massive win for patients and their families. The approval, given to Boston-area biotech Amylyx Pharmaceuticals, comes after two years of long and contentious debates over the drug’s effectiveness between advocacy groups and FDA scientists, following the readout of a mid-stage clinical trial in September 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

CHICAGO — While the later-stage drug developers in the geographic atrophy field are near the finish line, Johnson & Johnson’s Janssen is taking a more deliberate route, with a treatment that it hopes to be a one-time fix.

The Big Pharma will take its Hemera Biosciences-acquired gene therapy into a Phase II study later this year in patients with GA, a common form of age-related macular degeneration that impacts about five million people worldwide. To get there, Janssen touted early-stage safety data at the American Academy of Ophthalmology annual conference Saturday morning, half a day after competitors Apellis and Iveric Bio revealed their own more-detailed Phase III analyses.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Nooman Haque, head of life sciences and healthcare at Silicon Valley Bank, and John Carroll

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

Up­dat­ed: Al­ny­lam re­in­forces APOL­LO-B patisir­an da­ta be­fore head­ing to the FDA

Weeks after uncorking some mostly positive data for patisiran in transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, Alnylam is bolstering its package with new exploratory and subgroup data before shipping it off to regulators.

The RNAi drug maintained “generally consistent” benefits in efficacy and quality of life across several prespecified subgroups at month 12, Alnylam announced on Friday afternoon, including age, baseline tafamidis use, ATTR amyloidosis type, baseline six-minute walk test score and others.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Jerome Durso, Intercept Pharmaceuticals CEO

In­ter­cep­t's OCA fails a PhI­II NASH tri­al, rais­ing fresh doubts about its years­long quest for an OK

Intercept Pharmaceuticals has run into another big setback in its yearslong quest to win an approval for OCA in NASH. The biotech put out word Friday morning that its Phase III REVERSE study failed the primary endpoint for the liver disease, sending its share price into a tailspin.

There was no significant improvement in fibrosis among the patients suffering from cirrhosis who were treated with obeticholic acid, with investigators hunting for a minimum 1-stage histological improvement in the disease after 18 months of therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric, Biohaven CEO (Photo Credit: Andrew Venditti)

As Amy­lyx de­ci­sion waits in the wings, Bio­haven’s ALS drug sinks (again) in plat­form tri­al

The FDA’s decision on Amylyx’s ALS drug is set to come out sometime Thursday. In a space with few drugs, any approval would be a major landmark.

But elsewhere in the ALS field, things are a bit more tepid.

Thursday morning, Biohaven announced that its drug verdiperstat failed its arm of an ALS platform trial led by Massachusetts General Hospital. According to a press release, the drug did not meet its primary endpoint — improvement on an ALS functional status test — or any key secondary endpoints at 24 weeks. The trial had enrolled 167 patients, giving them either verdiperstat or placebo twice a day.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.